

Parameter	Supplement (n=47)	Placebo (n=28)	p value
Smoke (%)			0.13
Never	21.3	35.7	
Past	55.3	57.1	
Actual	23.4	7.1	
Familiarity for diabetes (%)	72.3	64.3	0.60
Arterial hypertension (%)	74.5	78.6	0.78
Ischemic heart disease (%)	27.6	35.7	0.61
Coronary artery disease (%)	38.3	35.7	0.99
Carotid stenosis (%)	23.4	25.0	0.99
Peripheral chronic obliterating arterial disease (%)	6.4	3.4	0.99
Cerebral vascular disease (%)	10.6	3.4	0.40
Thrombosis (%)	21.3	25.0	0.78
Chronic kidney disease (%)	27.6	32.1	0.79
Diabetic retinopathy (%)	12.8	17.8	0.74
Diabetic neuropathy (%)	19.1	14.3	0.76
Neoplasia (%)	14.9	14.3	0.99
Chronic liver disease (%)	8.5	10.7	0.99
Hepatosteatosi s (%)	27.6	17.8	0.41
Chronic pulmonary disease (%)	4.2	14.3	0.19
Hypoglycemic drugs (%)			
Basal insulin	27.6	35.7	0.60
Metformin	83.0	75.0	0.55
Pioglitazone	4.2	0.0	0.53
Repaglinide	2.1	3.4	0.99
Sulphonylureas	14.9	14.3	0.99
Acarbose	12.8	14.3	0.99
SGLT2 inhibitors	46.8	57.1	0.48
DPP-4 inhibitors	34.0	21.4	0.30
GLP-1 agonist receptors	23.4	35.7	0.29
Cardiovascular therapies (%)			
Anti-hypertensive	72.3	78.6	0.60

ACE-inhibitors	27.6	39.3	0.32
Sartans	38.3	25.0	0.31
B-blockers	53.2	53.6	0.99
Calcium-antagonist	36.2	28.6	0.61
Diuretics	31.9	32.1	0.99
Apha1-blockers	8.5	21.4	0.16
Statins	65.9	67.8	0.40
Ezetimibe	8.5	10.7	0.40
Omega	17.0	17.8	0.42
Fibrates	4.3	3.4	0.42
Antiplatelet agents	51.1	42.8	0.63
Anticoagulants	6.4	0.0	0.29

Table S1. Additional baseline characteristics in the ITT population. Other measured baseline characteristics in addition to those in Table 1. Data refers to all the enrolled patients, they are reported as n (%), unless otherwise specified. Statistical test used was the non parametric Mann-Whitney U test.